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Abstract
Objective
Diagnosis of childhood tuberculosis is limited by the paucibacillary respiratory samples
obtained from young children with pulmonary disease. We aimed to compare accuracy of
the Xpert1MTB/RIF assay, an automated nucleic acid amplification test, between induced
sputum and gastric lavage samples from young children in a tuberculosis endemic setting.
Methods
We analyzed standardized diagnostic data from HIV negative children younger than four
years of age who were investigated for tuberculosis disease near Cape Town, South Africa
[2009–2012]. Two paired, consecutive induced sputa and early morning gastric lavage
samples were obtained from children with suspected tuberculosis. Samples underwent
Mycobacterial Growth Indicator Tube [MGIT] culture and Xpert MTB/RIF assay. We com-
pared diagnostic yield across samples using the two-sample test of proportions and McNe-
mar’s χ2 test; and Wilson’s score method to calculate sensitivity and specificity.
Results
1,020 children were evaluated for tuberculosis during 1,214 admission episodes. Not all
children had 4 samples collected. 57 of 4,463[1.3%] and 26 of 4,606[0.6%] samples tested
positive forMycobacterium tuberculosis on MGIT culture and Xpert MTB/RIF assay respec-
tively. 27 of 2,198[1.2%] and 40 of 2,183[1.8%] samples tested positive [on either Xpert
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MTB/RIF assay or MGIT culture] on induced sputum and gastric lavage samples, respec-
tively. 19/1,028[1.8%] and 33/1,017[3.2%] admission episodes yielded a positive MGIT cul-
ture or Xpert MTB/RIF assay from induced sputum and gastric lavage, respectively.
Sensitivity of Xpert MTB/RIF assay was 8/30[26.7%; 95% CI: 14.2–44.4] for two induced
sputum samples and 7/31[22.6%; 11.4–39.8] [p = 0.711] for two gastric lavage samples.
Corresponding specificity was 893/893[100%;99.6–100] and 885/890[99.4%;98.7–99.8]
respectively [p = 0.025].
Conclusion
Sensitivity of Xpert MTB/RIF assay was low, compared to MGIT culture, but diagnostic per-
formance of Xpert MTB/RIF did not differ sufficiently between induced sputum and gastric
lavage to justify selection of one sampling method over the other, in young children with sus-
pected pulmonary TB.
Trial Registration
ClinicalTrials.gov NCT00953927
Introduction
Children comprise approximately 6% of the 9 million incident cases of TB globally [1]. Timely,
accurate diagnosis of childhood TB across sub-Saharan Africa is hindered by lack of fast, reli-
able, available diagnostic tests; difficulty in obtaining diagnostic expectorated sputum samples;
and the paucibacillary nature of childhood TB disease, particularly when co-infected with HIV
[2]. These challenges highlight the importance of obtaining optimal respiratory samples to
allow early diagnosis and initiation of therapy for children with TB. The Xpert MTB/RIF assay
[Cepheid, Sunnyvale, CA, USA] is an automated nucleic acid amplification test that utilises the
GeneXpert1 platform to detectMycobacterium tuberculosis and rifampin resistance in less
than 2 hours. Sample processing/preparation, PCR amplification and detection are integrated
into a single self-enclosed test cartridge, and following sample loading, all steps in the assay are
completely automated and self-contained [3,4].
Few studies have compared diagnostic yield of the Xpert MTB/RIF assay between induced
sputum and gastric lavage samples, which contain swallowed bacilli originating from the respi-
ratory tract, in young children. Most of these studies are characterized by small sample sizes;
wide age band; unmatched or unpaired induced sputum and gastric lavage samples; and
include meta-analyses [5–8]. It is important to guide programmatic recommendations on
whether increased use of the Xpert MTB/RIF assay should influence choice of sampling
method; or whether, for example, Mycobacterial Growth Indicator Tube [MGIT] [Becton
Dickinson, Sparks, USA] culture should be preferred over Xpert MTB/RIF for certain samples.
Our objective was to compare diagnostic yield of the Xpert MTB/RIF assay on matched
induced sputum and gastric lavage samples, obtained from young children with suspected TB
in a clinical trial setting, to inform choice of specimen sampling for paediatric TB diagnosis.
Methods
Data were collected during an infant TB vaccine trial [2009–2012] conducted by the South
African Tuberculosis Vaccine Initiative [SATVI] in a rural region about 100 km north of Cape
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Town, South Africa [9]. The incidence of TB disease in infants was reported as 3% in this study
community in 2010 [10]. As previously described [9,11], healthy 4–6 month-old infants were
recruited if they had received all age-appropriate routine immunizations, were HIV negative,
and if latent TB infection and active TB disease had been excluded. Children were followed
quarterly for at least two years to identify signs, symptoms, or household exposure that merited
investigation for suspected TB disease i.e.1] weight loss in the preceding two months, 2] cough
for more than two weeks without improvement, 3] failure-to-thrive, or 4] conversion to a posi-
tive QuantiFERON TB Gold In-Tube test or positive Mantoux test. Symptomatic children
were readmitted if they had new symptoms, or if they were not previously treated for TB dis-
ease and no alternative diagnosis of their symptoms had been made, or if a previous course of
anti-tuberculous treatment had since been completed. Children receiving prophylactic isonia-
zid monotherapy were also readmitted for investigation if they became symptomatic. Asymp-
tomatic children were admitted for investigation in a dedicated trial specific case verification
ward once for each new cohabiting household tuberculosis contact identified, hence the high
number of admissions, and readmitted only if they had continued exposure to an inadequately
treated cohabiting household tuberculosis contact. Two matched, consecutive induced sputa
and early morning gastric lavage samples were obtained from children with suspected TB.
Obtained samples underwent Xpert MTB/RIF assay and MGIT culture and drug sensitivity
testing [9].
Induced sputum and gastric lavage sample collection have been described previously [9].
Briefly, gastric lavage was performed early in the morning after an overnight fast of at least 4
hours, for each of the first 2 days of admission. Based on age, 5–20 mL of 0.9% saline was
instilled and the same volume of gastric lavage fluid aspirated after 2–4 minutes, via a nasogas-
tric tube. The specimen was transported to the lab within 6 hours of collection. Sputum induc-
tion was performed 3–4 hours later by a trained professional nurse. The sputum induction
procedure was performed in a dedicated procedure room with negative pressure ventilation
providing at least 72 air changes per hour by externally vented fan. Standard disinfection and
infection control procedures were observed, including use of N95 particulate filter masks by
staff. Continuous pulse and oxygen saturation monitoring was used. 100 micrograms of salbu-
tamol was administered prior to the procedure, via a metered dose inhaler with spacer and face
mask. Ten minutes after bronchodilator administration, nebulization was performed with 5
mL of sterile hypertonic 5% saline solution, via jet nebulizer attached to cylinder oxygen supply
flowing at 3–5 liters/min. Approximately 2.5 mL of induced sputum sample was then obtained
by suctioning of the nasopharynx, using a sterile mucus extractor, and transported within 4
hours of collection to the laboratory. Chest physiotherapy was not employed as part of the
induced sputum procedure.
Using Xpert MTB/RIF assay and MGIT culture results, we compared diagnostic yield from
induced sputum to that from gastric lavage samples; and determined sensitivity of Xpert MTB/
RIF assay in each sample type. We defined a TB case by positive result forMycobacterium
tuberculosis on any test during a given admission event. For example, an admission event was
considered to be a case if there was a positive result on at least one of MGIT culture or Xpert
MTB/RIF assay, and not a case if negative on both tests. We report three categories of diagnos-
tic yield: crude yield, incremental yield and differences in yield. Crude yield was defined as
number ofMycobacterium tuberculosis positive cases divided by number of all admission epi-
sodes investigated, for each category of sample. Crude yield was calculated for Xpert MTB/RIF,
MGIT culture, and for a combination of the two tests [MGIT culture or Xpert MTB RIF assay].
Incremental yield was defined as the additional gain in crude yield afforded by testing a second
sample of induced sputum or gastric lavage, respectively. The numerator for incremental yield
was defined as the number of TB cases that might be identified by a specified test, either Xpert
Xpert1 Assay in Paired Induced Sputum and Gastric Lavage Samples
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MTB/RIF or MGIT culture, or combination of Xpert MTB/RIF and MGIT culture, on a second
sample, which were not identified by the first sample. The denominator for incremental yield
was the number of admission events with results for two samples of either induced sputum or
gastric lavage. For differences in yield, we used the number of admission events positive on
either Xpert MTB/RIF assay or MGIT culture on any sample from the same admission event as
the denominator. We derived four different numerators for our determination of whether dif-
ferences in yield were significant. These were 1] admission events positive on Xpert MTB/RIF
assay on first induced sputum, 2] admission events positive on Xpert MTB/RIF assay on first
gastric lavage sample, 3] admission events positive on Xpert MTB/RIF assay on either first or
second induced sputum sample and 4] admission events positive on Xpert MTB/RIF assay on
either first or second gastric lavage sample.
Diagnostic yield is reported using proportions and 95% confidence intervals [CI]. We tested
whether differences in yield between induced sputum and gastric lavage are significant using
the two sample test of proportions. The McNemar’s χ2 test was used to compare matched
observations. Sensitivity and specificity of Xpert MTB/RIF assay was compared between
induced sputum and gastric lavage samples, using MGIT culture from all 4 samples during the
same admission event as the gold standard. The denominator for sensitivity was the number of
TB cases defined by a positive MGIT culture forMycobacterium tuberculosis on at least one of
the 4 paired samples [induced sputum or gastric lavage]. The denominator for specificity was
the total number of MGIT culture negative admission events. Not all admission events had two
gastric lavages and two induced sputa collected and only admission events with complete
results were considered in the denominator for specificity. Sensitivity and specificity were cal-
culated using the Wilson’s score method. All statistical tests were two-sided at α of 0.05. Analy-
sis was done in STATA1 statistical software version 13.1 for Windows [12].
The clinical trial during which the data were collected received regulatory approval from the
University of Cape Town Human Research Ethics Committee; and was registered with the
South African National Clinical Trials Register [DOH-27-0109-2654] and ClinicalTrials.gov
[NCT00953927] [9]. Parents or legal guardians provided written, informed consent for partici-
pation of their children.
Results
Diagnostic data were available for 1,020 children evaluated for TB disease during 1,214 admis-
sions. Baseline characteristics of all admission events are provided in Table 1. Of 1214 admis-
sion events, 693 had one or more of the constitutional symptoms of TB. 44 had weight loss,
196 had cough of more than 2 weeks, 594 had failure to thrive, 430 resided with a household
member with a positive sputum smear and 36 had other symptoms. As shown in the supple-
mentary tables (S1 Table and S2 Table), not all admission events had the full complement of 2
induced sputa and 2 gastric lavage aspirate results available for analysis. We used results that
gave positive and negative results forMycobacterium tuberculosis. There were 1038 first admis-
sions, 152 second admissions, 23 third admissions and 1 fourth admission.
The youngest child diagnosed as a TB case was aged 6.7 months and the oldest 40.5 months;
with median age at TB case diagnosis of 21.6 months [IQR: 15.3–29.6]. A total of 57 of 4,463
[1.3%] samples tested positive forMycobacterium tuberculosis on MGIT culture and 26 out of
4,606 [0.6%] samples tested positive on Xpert MTB/RIF assay [Fig 1]. Nineteen children tested
positive, on either MGIT culture or Xpert MTB/RIF assay, from the first or second induced
sputum sample [n = 19/1028; 2%] and 33 children tested positive, on either MGIT culture or
Xpert MTB/RIF assay, from the first or second gastric lavage sample [n = 33/1017; 3%]
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[Table 2]. There was no statistically significant difference in crude yield of Xpert MTB/RIF
between induced sputum and gastric lavage samples.
Discussion
We report a rigorous, standardized, head-to-head comparison of the diagnostic accuracy of
Xpert MTB/RIF assay in induced sputum and gastric lavage samples from more than one thou-
sand young HIV-negative children with suspected TB. Our study suggests that diagnostic per-
formance of Xpert MTB/RIF assay by induced sputum or gastric lavage sampling method is
similar, which would support current recommendations by the South African Department of
Health [13]. However, we are unable to make a definitive conclusion that there is no difference
in performance, due to limited statistical power. We report low sensitivity, moderate-high posi-
tive predictive value, high negative predictive value, and very high specificity for Xpert MTB/
RIF assay in both sampling techniques.
The relatively low MGIT culture and Xpert MTB/RIF assay positivity rates forMycobacte-
rium tuberculosis that we observed may be explained by the generally mild clinical forms of TB
disease in a clinical trial setting with active TB surveillance that generally enabled early case
detection and timely referral of children who required isoniazid prophylactic therapy, exclu-
sion of children with co-morbid diseases such as HIV and the young age of the study popula-
tion. The minimum criteria of admission for investigation to our trial-specific case verification
ward was a history of household contact with an individual with pulmonary TB, hence the
high number of admissions. These factors have been observed in several studies as potential
causes of low rates of culture-positive TB disease in children [8,14–17]. We report lower sensi-
tivity of Xpert MTB/RIF assay in young children than the 62% reported for children aged up to
15 years in a meta-analysis of 15 studies in 2015 [5]. The minimum number of bacilli that can
be detected with 95% confidence [i.e. the analytical limit of detection] is 131 colony forming
units [CFU] [95% CI: 106–176] per ml of clinical sputum for Xpert MTB/RIF assay [3,4], 10–
100 CFU/ ml for MGIT culture [18,19], and 5,000–10,000 CFU/ml for smear microscopy [20].
The paucibacillary nature of samples from young children partly explains the lower sensitivity
of Xpert MTB/RIF assay than that observed in adults. Use of a reference standard that takes
into consideration results of 4 samples taken over the same admission event increases accuracy
of the reference standard, but was found to lead to lower sensitivity, compared to when sensi-
tivity was determined using MGIT culture results from one specimen only. It is hard to deter-
mine whether differences in volume of sample obtained using the different specimen collection
Table 1. Demographic characteristics at baseline of all admission events.
Variable Placebo arm Vaccine arm Overall
Total admission events[N] 601[49%] 613[51%] 1214[100%]
Male 281[47%] 278[45%] 559[46%]
Age at admission[Months] 16.4[11.8;21.3] 17.1[12.4;22.5] 16.8[12.0;22.1]
Weight at admission[Kgs] 9.7[8.4–10.8] 10.0[8.6–11.3] 9.9[8.5–11.1]
Race
Mixed 528[88%] 528[86%] 1056[87%]
Black 72[12%] 84[14%] 156 [13%]
Asian 1[<1%] 1[<1%] 2[<1%]
White 0[0%] 0[0%] 0[0%]
Footnote: Data are N [%] or median [interquartile range]. Kgs = Kilograms.
doi:10.1371/journal.pone.0141623.t001
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procedures, i.e. 5–20 ml for gastric lavage based on age and 2.5 ml for induced sputum, and
splitting of samples for MGIT culture and Xpert MTB/RIF assay had an effect on results
obtained through the two specimen collection approaches in our study. We believe this ques-
tion can best be answered through a study specifically designed to investigate effect of sample
volume by the different specimen collection approaches on yield. The research team had long-
standing experience of almost ten years in specimen collection of both induced sputum and
gastric lavage samples in trial settings and all staff performing these procedures were re-trained.
Thus, sampling differences due to differences in rigor of collection of specimens or a learning
curve in collection of either of the two specimens is unlikely to have occurred or significantly
impacted our findings.
Fig 1. Study schema. Key: MGIT culture = Mycobacterial Growth Indicator Tube Culture;MOTT = Mycobacteria other thanMycobacterium tuberculosis.
doi:10.1371/journal.pone.0141623.g001
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Chang et al suggested the following factors as plausible reasons for false-positive Xpert
MTB/RIF assay results: sub-clinical TB relapse, treatment failure due to multi-drug resistant
TB and excretion of residual persistent DNA from deadMycobacterium tuberculosis in patients
on TB treatment [8]. In our study, only 2 out of 167 children admitted more than once had a
positive Xpert MTB/RIF assay result. They did not have a prior diagnosis of TB and all MGIT
cultures and smear microscopy on them were negative. No case of multi-drug resistant TB or
TB retreatment was reported in our study. Additionally, the observed specificity of almost
100% [i.e. false positivity rate of<0.006] suggests that false positive Xpert MTB/RIF assay
results are unlikely. There are few studies in young children that compare performance of
induced sputum and gastric lavage samples using Xpert MTB/RIF assay. For example, Bates
et al [7] found no significant difference in diagnostic accuracy of Xpert MTB/RIF assay
between gastric lavage and sputum. However, this study used expectorated sputum, un-
Table 2. Crude yield from induced sputum and gastric lavage samples forMycobacterium tuberculosis.
Sample Positive Xpert MTB/RIF
assay
Positive MGIT culture Positive MGIT culture or Xpert MTB/RIF
assay
First induced sputum n = 7/1,157 [0.6%; 0.3–1.2] n = 17/1,107 [1.5%; 1.0–
2.4]
n = 18/1,093 [1.6%; 1.0–2.6]
First or second induced sputum n = 8/1,128 [0.7%; 0.4–1.4] n = 19/1,060 [1.8%; 1.2–
2.8]
n = 19/1,028 [1.8%; 1.2–2.9]
Incremental yield by second induced
sputum
n = 1/1,128 [0.1%; 0.0–0.5] n = 2/1,060 [0.2%; 0.1–
0.7]
n = 1/1,028 [0.1%; 0.0–0.5]
First gastric lavage n = 4/1,154 [0.3%; 0.1–0.9] n = 16/1,094 [1.5%; 0.9–
2.4]
n = 18/1,068 [1.7%; 1.1–2.6]
First or second gastric lavage n = 13/1,131 [1.1%; 0.7–2.0] n = 25/1,048 [2.4%; 1.6–
3.5]
n = 33/1,017 [3.2%; 2.3–4.5]
Incremental yield by second gastric
lavage
n = 9/1,131 [0.8%; 0.4–1.5] n = 9/1,048 [0.9%; 0.5–
1.6]
n = 15/1,017 [1.5%; 0.9–2.4]
Any induced sputum or gastric lavage 18/1,103 [1.6%; 1.0–2.6] 36/1,188 [3.0%; 2.2–4.2] 42/1,214 [3.5%; 2.6–4.6]
Data are number of positive admission events, percentage and 95% conﬁdence interval. Numerator is number of admission events with a positive result.
Denominator is number of admission events in which the test [or combination of tests] was performed. An admission event was deﬁned as a case if at
least one of the test results was positive, and negative if all test results were negative. Not all admission events had two gastric lavages and two induced
sputa collected, hence minor variation in the denominator. There were no signiﬁcant differences in yield of Xpert MTB/RIF assay between induced sputum
and gastric lavage samples using our deﬁnition of Yield difference Table 3.
doi:10.1371/journal.pone.0141623.t002
Table 3. Differences in yield of Xpert MTB/RIF assay test by sample or category of sample.
Specimen n/N Yield Specimen n/N Yield Yield difference P-value
First induced sputum 7/37 18.9% [9.5;34.2] Vs. First gastric lavage 4/38 10.5% [4.2;24.1] 8.4% [-7.6;24.3] 0.304
First induced sputum 7/37 18.9% [9.5;34.2] Vs. Any gastric lavage1 13/37 35.1% [21.8;51.2] -16.2% [-36.1; 3.7] 0.116
Any induced sputum1 8/36 22.2% [11.7;38.1] Vs. First gastric lavage 4/38 10.5% [4.2;24.1] -11.7% [-5.0;28.4] 0.173
Any induced sputum1 8/36 22.2% [11.7;38.1] Vs. Any gastric lavage1 13/37 35.1% [21.8;51.2] -12.9% [-33.4;7.6] 0.223
Data are n/N [95% conﬁdence interval]. Numerator is number of positive results on Xpert MTB/RIF assay only. Denominator is number of positive results
on either MGIT culture or Xpert MTB/RIF assay. P-values are not adjusted for multiple comparisons.
1Numerator was deﬁned as positive Xpert MTB/RIF assay result on at least one of the two samples [i.e. ﬁrst or second induced sputum, or, ﬁrst or second
gastric lavage]. We observed sensitivity of 23%, 9%, 27% and 23% when Xpert MTB/RIF was performed on one induced sputum, one gastric lavage, two
induced sputa and two gastric lavage samples respectively. Diagnostic sampling by induced sputum or gastric lavage did not signiﬁcantly affect speciﬁcity,
or positive or negative predictive values of the Xpert MTB/RIF assay, using MGIT culture as the gold standard [Table 4].
doi:10.1371/journal.pone.0141623.t003
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matched samples, and enrolled older children aged up to 15 years, with more severe clinical
presentation of TB and multiple co-morbidities, including HIV prevalence of 31% [7]. A 2015
systematic review on diagnostic accuracy of Xpert MTB/RIF assay in children younger than 16
years did not show a significant difference in sensitivity of Xpert MTB/RIF assay with use of
induced or expectorated sputum as compared to use of gastric lavage. It reported a sensitivity
of 62% [51–73%] and 66% [51–81%] respectively. Besides inclusion of older children as com-
pared to our study, most studies were conducted on inpatients and included both HIV negative
and positive children [5].
Our study participants were HIV negative children with mild or moderately severe disease
at diagnosis and little comorbidity. This study population differs from that in many sub-Saha-
ran African countries, where HIV and other comorbidities, such as malnutrition, are common
and these factors have been shown to influence performance of Xpert MTB/RIF assay [21].
Given the heterogeneity in findings of existing studies comparing performance of Xpert MTB/
RIF assay in HIV positive and HIV negative children [7,14,22], it remains unclear how HIV
prevalence might affect Xpert MTB/RIF assay performance in induced sputum and gastric
lavage samples. Studies to evaluate specimen processing techniques to optimise diagnostic
yield of the Xpert MTB/RIF assay, particularly from non-respiratory samples, may further
guide recommendations for sample collection in pulmonary and extra-pulmonary TB [23].
The primary limitation of our study was the small number of TB cases observed, despite the
large sample size, which may have limited our statistical power to detect small differences in
yield and sensitivity of Xpert MTB/RIF assay between induced sputum and gastric lavage sam-
ples [24]. A major strength of our study is the matched design, in which two paired induced
sputum and two gastric lavage samples were obtained from study participants, using a stan-
dardized TB investigation protocol. We also used results of four samples to determine TB dis-
ease status, this increases accuracy of the gold standard considering the limited sensitivity of
MGIT culture.
In conclusion, we observed relatively low yield of Xpert MTB/RIF assay, compared to
MGIT culture, in both induced sputum and gastric lavage aspirate samples in HIV negative
young children in a clinical trial setting in a high TB burden country. Our findings suggest
Xpert MTB/RIF assay performance is similar between induced sputum and gastric lavage
Table 4. Diagnostic accuracy of Xpert MTB/RIF assay in induced sputum and gastric lavage samples.
Specimen Sensitivity Speciﬁcity Positive Predictive
Value
Negative Predictive Value
First induced sputum n = 7/31 [22.6%; 11.4–
39.8]
n = 908/908 [100%; 99.6–
100]
n = 7/7 [100%; 64.6–100] n = 908/932 [97.4%; 96.2–
98.3]
First or second induced
sputum1
n = 8/30 [26.7%; 14.2–
44.4]
n = 893/893 [100%; 99.6–
100]
n = 8/8 [100%; 67.6–100] n = 893/915 [97.6%; 96.4–
98.4]
First gastric lavage n = 3/32 [9.4%; 3.2–24.2] n = 902/903 [99.9%; 99.4–
100]
n = 3/4 [75.0%; 30.1–
95.4]
n = 902/931 [96.9%; 95.6–
97.8]
First or second gastric
lavage1
n = 7/31 [22.6%; 11.4–
39.8]
n = 885/890 [99.4%; 98.7–
99.8]
n = 7/12 [58.3%; 32.0–
80.7]
n = 885/909 [97.4%; 96.1–
98.2]
The denominator for sensitivity was any positive MGIT culture on any induced sputum or gastric lavage sample taken during the same admission event.
The denominator for speciﬁcity was number of admission events with negative MGIT culture on two induced sputa and two gastric lavages [i.e. all 4
results available and negative]. Not all admission events had the full complement of two gastric lavages and two induced sputa collected, or with negative
or positive results for inclusion in this analysis. For example, 159 samples were missing/not obtained hence variation in the denominator. See
Supplementary S1 and S2 Tables for a full breakdown of results from processing of samples.
1Xpert MTB/RIF assay was considered positive if at least one of the two test results on the ﬁrst or second sample was positive.
doi:10.1371/journal.pone.0141623.t004
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samples. However, our study had limited statistical power to demonstrate small differences
between these two sampling methods, given the low diagnostic yield that we observed. Larger
comparative studies in this paediatric population would be required to answer this question
conclusively.
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